Browse > Article

A Case of Pleural Effusion in a Patient with Heart Failure with Preserved Ejection Fraction Improved by A Combined Korean-Western Medicine Approach  

Ha, Won Jung (Dept. of Clinical Korean Medicine, Graduate school, Kyung-Hee University)
Seo, Yuna (Dept. of Clinical Korean Medicine, Graduate school, Kyung-Hee University)
Lee, Young seon (Dept. of Clinical Korean Medicine, Graduate school, Kyung-Hee University)
Cho, Ki-Ho (Dept. of Cardiology and Neurology, College of Korean medicine, Kyung-Hee Universit)
Mun, Sang-Kwan (Dept. of Cardiology and Neurology, College of Korean medicine, Kyung-Hee Universit)
Jung, Woo-Sang (Dept. of Cardiology and Neurology, College of Korean medicine, Kyung-Hee Universit)
Kwon, Seungwon (Dept. of Cardiology and Neurology, College of Korean medicine, Kyung-Hee Universit)
Publication Information
The Journal of the Society of Stroke on Korean Medicine / v.22, no.1, 2021 , pp. 45-56 More about this Journal
Abstract
■ Background Heart Failure with Preserved Ejection Fraction(HFpEF) is a heart failure that appears to have normal contraction function. In the case of HFpEF, no pharmacological therapy has been found to improve clinical prognosis, so it should be approached as an symptomatic treatment, therefore alternatives are needed due to concerns over adverse effects such as electrolyte imbalance caused by medication. ■ Case report A 81 year old female patient with Heart Failure with Preserved Ejection Fraction(HFpEF) patient complained dyspnea. Herbal prescription Mokbanggi-tang and Oryeongsan was administered on 6th day and 8th day respectively since the symptoms started. The NYHA Classification and Chest X-ray had been evaluated during the treatment period. Until the 7th day, the patient was classified as Class II, and when discharged from the hospital on the 28th day, it gradually improved and was classified as Class II. Chest X-Ray took on 2nd day showed pleural effusion and it was aggravated until 13th day. Follow up Chest X-Ray showed improving state of pleural effusion from 20th day and gradually got better. Mokbanggi-tang treatment continued for 52 days and stopped on 58th day. After Mokbanggi-tang treatment ended, only Oryeongsan treatment was maintained. ■ Conclusion The present case report suggests that Korean-Western medicine approach with Mokbangki-tang and Oryeongsan might be effective to pleural effusion and heart failure symptoms such as poor physical activity shown in a NYHA Classification. This shows that Mokbanggi-tang and Oryeongsan can be a therapeutic option as a treatment for patient with Heart Failure with Preserved Ejection Fraction(HFpEF).
Keywords
Pleural Effusion; Heart Failure with Preserved Ejection Fraction; HFpEF; Mokbanggi-tang; Mokuboito; Oryeongsan;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Poelzl G, Ess M, Mussner-Seeber C, Pachinger O, Frick M, Ulmer H. Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. Eur J Clin Invest. 2012;42:153-163.   DOI
2 Shuji YAKUBO, Yuko KINOSHITA, Yasuyuki ARAKAWA, Masanao TAKA-HAsHI, Susumu KITANAKA. Clinical evaluation of Moku-boi-to(Mu-Fang-Yi-Tang):A Japanese and Chinese traditional medicine for heart failure. J.Trad.Med. 2002;19:159-163.
3 Kim YD. Heart Failure with Preserved Ejection Fraction: Current Diagnostic and Therapeutic Approach. 2016;90(1):20-25.
4 Lee JH, Koo BK. Pleural Effusion in Cardiovascular Disease. Korean J Med. 2011;81(2):161-166.
5 조기호, 권승원. 경계 너머의 한방처방. 경기:물고기숲. 2012:201.
6 조한진, 이경섭. 목방기탕(木防己湯)이 강심이뇨 및 심장박동에 미치는 영향. 대한한의학회지. 1984;5(1): 28-34.
7 Nishida S, Satoh H. Vascular pharmacology of mokuboito(mu-fang-yi-tang) and its constituents on the smooth muscle and the endothelium in rat aorta. Evid Based Complement Alternat Med. 2007;4:335-341.   DOI
8 Satoh H, Sperelakis N. Review of some actions of taurine on ion channels of cardiac muscle cells and others. Gen Pharmacol. 1998;30:451-463.   DOI
9 한의과대학 방제학교수 공편저. 방제학. 서울:영림사; 2003:504-6.
10 Ito Y. Pathophysiology of the Goreisan show lowering of osmolality set point. Japanese Journal of Oriental Medicine. 1978;28:91-9.
11 Isohama Y. Modulation of aquaporin water channel function by Kampo medicines. Kampo and the newest therapy. 2008;17:27-35.
12 Kim SY. Influence of Goryeosin infusion solution on the change of serum electrolytes in rats. Dajeon Univ 1990:1-38.
13 Hirotaka Ezaki, Makoto Ayaori, Hiroki Sato, Yoshio Maeno, Masanori Taniwaki, Takayuki Miyake, Masami Sakurada. Effects of Mokuboito, a Japanese Kampo medicine, on symptoms in patients hospitalized for acute decompensated heart failure - A prospective randomized pilot study. Journal of Cardiology. 2019;74:412-417.   DOI
14 張仲景. 元.鄧珍本金匱要略2-4b~2-5a. 燎原書店復刻版. 1988. 86-87.
15 Park JJ, Choi DJ. Treatment of Heart Failure with Reduced Ejection Fraction: Current Update. Korean J Med. 2015;88(2):127-134.   DOI
16 Bennett JA, Riegel B, Bittner V, Nichols J. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002;31(4):262-70.   DOI
17 Seiichiro Nishida, Hiroyasu Satoh. Vascular Pharmacology of Mokuboito (Mu-Fang-YiTang) and Its Constituents on the Smooth Muscle and the Endothelium in Rat Aorta. eCAM. 2007;4(3):335-341.
18 Na SJ, Bae SH. Optimal Management of Heart Failure with Preserve Ejection Fraction. Korean J Med. 2015;88(2):135-141.   DOI
19 EZAKI H, INOKUCHI T, TANIWAKI M, YAMAMOTO H, DOI H, MIYAKE T, SAKURADA M. Efficacy of Mokuboito in Patients with Severe Intractable Heart Failure. Kampo Medicine. 2016;67(2):169-177.   DOI
20 Otsuka,K. Kampo-lgaku(漢方医学), Osaka:Sougen-sha. 1973:150.
21 Kurita T, Nakamura K, Tabuchi M, Orita M, Ooshima K, Higashino H. Effects of Goreisan: a traditional Japanese Kampo medicine, on aquaporin 1, 2, 3, 4 and V2R mRNA expression in rat kidney and forebrain. J Med Sci. 2011;11(1):30-8.   DOI
22 Hirotaka Ezaki, Makoto Ayaori, Hiroki Sato, Yoshio Maeno, Masanori Taniwaki, Takayuki Miyake, Masami Sakurada. Effects of Mokuboito, a Japanese Kampo medicine, on symptoms in patients hospitalized for acute decompensated heart failure - A prospective randomized pilot study. Journal of Cardiology. 2019;74:412-417.   DOI
23 Jeong MJ, Kang KW, Kang JY et al. An Overview of the Applicability of Oryung-san as an Antihypertensive Agent. J. Int. Korean Med. 2017;38(4):443-454.   DOI